Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Optimizing twin prime editing components for scalable genome editing and therapy in spinocerebellar ataxia type 3.

Created on 06 Jul 2026

Authors

Lee Wha Gwon, Jung Bae Seong, Hyeon-Gu Yeo, Yeounsun Oh, Junghyung Park, Jinyoung Won, Sang Je Park, Young-Hyun Kim, Jae-Won Huh, Aryun Kim, Kwang-Hyun Park, Youngjeon Lee, Seung Hwan Lee

Published in

Molecular therapy. Nucleic acids. Volume 37. Issue 3. Pages 102988. Sep 08, 2026. Epub Jun 17, 2026.

Abstract

Recent advances in prime editing technologies using CRISPR modules fused with reverse transcriptase (RT) have enabled efficient and precise reprogramming of target genomic sequences. Twin prime editing using two coordinated prime editor complexes is a promising strategy for inducing extensive genomic modifications via reverse-transcribed complementary templates. However, current twin prime editing systems still require improvements in editing efficiency, accuracy, and intended edit predictability. Here, efficiency and precision of twin prime editing were enhanced via engineering and optimizing conventional SpCas9(H840A)-RT-based prime editor (twin-PE) components. A La-domain-fused prime editor (La-twin-PE) and optimized prime editing guide RNAs (pegRNAs) were developed, achieving a 1.75 ± 0.21-fold increase in gene editing efficiency at multiple genomic loci in human-derived cell lines without increasing unintended indel or inaccurate editing. La-twin-PE facilitated efficient ∼2.8 kb GFP transgene knockin at target loci and eliminated the expanded polyQ tract in ATXN3 in an engineered human-derived mutant cell line modeling spinocerebellar ataxia type 3. The optimized twin prime editing platform facilitates highly efficient and scalable genomic engineering through streamlined pegRNA design, offering substantial potential for a broad spectrum of biotechnological and therapeutic applications.

PMID:
42405278
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement